Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies. 1997

G Osapay, and L Prokai, and H S Kim, and K F Medzihradszky, and D H Coy, and G Liapakis, and T Reisine, and G Melacini, and Q Zhu, and S H Wang, and R H Mattern, and M Goodman
Department of Chemistry and Biochemistry, University of California at San Diego, La Jolla 92093-0343, USA.

A series of cyclic somatostatin analogs containing a lanthionine bridge have been subjected to studies of structure-activity relationships. A direct synthesis of the thioether bridged analog (1) of sandostatin (SMS 201,995) and several lanthionine hexa-, hepta-, and octapeptides was carried out by using the method of cyclization on an oxime resin (PCOR) followed by condensation reactions in solution. The structures of the target peptides were analyzed by liquid secondary ion mass spectrometry (LSIMS) and subjected to high-energy collision-induced dissociation (CID) studies after opening of the peptide ring by proteolytic cleavage. The biological activities of these compounds have been evaluated by assaying their inhibitory potencies for the release of growth hormone (GH) from primary cultures of rat anterior pituitary cells, as well as by their binding affinities to cloned somatostatin receptors (SSTR1-5). The structural modification of sandostatin by introducing a lanthionine bridge resulted in a significantly increased receptor binding selectivity. The lanthionine octapeptide with C-terminal Thr-ol (1) showed similar high affinity for rat SSTR5 compared to somatostatin[1-14] and sandostatin. However, it exhibits about 50 times weaker binding affinity for mSSTR2b than sandostatin. Similarly, the lanthionine octapeptide with the C-terminal Thr-NH2 residue (2) has higher affinity for rSSTR5 than for mSSTR2B. Both peptides (compounds 1 and 2) have much lower potencies for inhibition of growth hormone secretion than sandostatin. This is consistent with their affinities to SSTR2, the receptor which is believed to be linked to the inhibition of growth hormone release by somatostatin and its analogs. The metabolic stability of lanthionine-sandostatin and sandostatin have been studied in rat brain homogenates. Although both compounds have a high stability toward enzymatic degradation, the lanthionine analog has a 2.4 times longer half-life than sandostatin. The main metabolites of both compounds have been isolated and identified by using an in vivo technique (cerebral microdialysis) and mass spectrometry.

UI MeSH Term Description Entries
D008297 Male Males
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D010903 Pituitary Gland, Anterior The anterior glandular lobe of the pituitary gland, also known as the adenohypophysis. It secretes the ADENOHYPOPHYSEAL HORMONES that regulate vital functions such as GROWTH; METABOLISM; and REPRODUCTION. Adenohypophysis,Anterior Lobe of Pituitary,Anterior Pituitary Gland,Lobus Anterior,Pars Distalis of Pituitary,Adenohypophyses,Anterior Pituitary Glands,Anterior, Lobus,Anteriors, Lobus,Lobus Anteriors,Pituitary Anterior Lobe,Pituitary Glands, Anterior,Pituitary Pars Distalis
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D000409 Alanine A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM. Abufène,Alanine, L-Isomer,L-Alanine,Alanine, L Isomer,L Alanine,L-Isomer Alanine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

G Osapay, and L Prokai, and H S Kim, and K F Medzihradszky, and D H Coy, and G Liapakis, and T Reisine, and G Melacini, and Q Zhu, and S H Wang, and R H Mattern, and M Goodman
November 1979, Biochemical and biophysical research communications,
G Osapay, and L Prokai, and H S Kim, and K F Medzihradszky, and D H Coy, and G Liapakis, and T Reisine, and G Melacini, and Q Zhu, and S H Wang, and R H Mattern, and M Goodman
October 2011, Journal of young pharmacists : JYP,
G Osapay, and L Prokai, and H S Kim, and K F Medzihradszky, and D H Coy, and G Liapakis, and T Reisine, and G Melacini, and Q Zhu, and S H Wang, and R H Mattern, and M Goodman
March 2017, Journal of Asian natural products research,
G Osapay, and L Prokai, and H S Kim, and K F Medzihradszky, and D H Coy, and G Liapakis, and T Reisine, and G Melacini, and Q Zhu, and S H Wang, and R H Mattern, and M Goodman
March 1986, Proceedings of the National Academy of Sciences of the United States of America,
G Osapay, and L Prokai, and H S Kim, and K F Medzihradszky, and D H Coy, and G Liapakis, and T Reisine, and G Melacini, and Q Zhu, and S H Wang, and R H Mattern, and M Goodman
March 2008, Journal of peptide science : an official publication of the European Peptide Society,
G Osapay, and L Prokai, and H S Kim, and K F Medzihradszky, and D H Coy, and G Liapakis, and T Reisine, and G Melacini, and Q Zhu, and S H Wang, and R H Mattern, and M Goodman
February 2001, Journal of peptide science : an official publication of the European Peptide Society,
G Osapay, and L Prokai, and H S Kim, and K F Medzihradszky, and D H Coy, and G Liapakis, and T Reisine, and G Melacini, and Q Zhu, and S H Wang, and R H Mattern, and M Goodman
August 1996, Metabolism: clinical and experimental,
G Osapay, and L Prokai, and H S Kim, and K F Medzihradszky, and D H Coy, and G Liapakis, and T Reisine, and G Melacini, and Q Zhu, and S H Wang, and R H Mattern, and M Goodman
January 1985, Progress in clinical and biological research,
G Osapay, and L Prokai, and H S Kim, and K F Medzihradszky, and D H Coy, and G Liapakis, and T Reisine, and G Melacini, and Q Zhu, and S H Wang, and R H Mattern, and M Goodman
June 2001, Endocrine regulations,
G Osapay, and L Prokai, and H S Kim, and K F Medzihradszky, and D H Coy, and G Liapakis, and T Reisine, and G Melacini, and Q Zhu, and S H Wang, and R H Mattern, and M Goodman
February 1999, The journal of peptide research : official journal of the American Peptide Society,
Copied contents to your clipboard!